Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2025 pubmed

Elevated Circulating Adipocyte-Fatty Acid Binding Protein Levels Predict Incident Ischemic Cardiovascular Events in a Longitudinal and Prospective AMI Aging Study.

Zhao. Xiaoxiao X; Zhao. Hanjun H; Chen. Runzhen R; Zhou. Jinying J; Li. Nan N; Li. Jiannan J; Yan. Shaodi S; Liu. Chen C; Zhou. Peng P; Chen. Yi Y; Song. Li L; Yan. Hongbing H

Key Findings

  • High circulating FABP4 predicts increased risk of ischemic cardiovascular events in older AMI patients.
  • Higher LL‑37 levels are associated with a reduced risk of these events (HR 0.65).
  • These associations remain significant after adjusting for age, sex, traditional heart disease risk factors, and medications.

Practical Outcomes

  • For biohackers, LL‑37 appears to be a potentially protective marker, but the study does not test any ways to raise its levels. Monitoring LL‑37 could inform risk assessment, yet there’s no proven supplement or protocol yet; focus on overall anti‑inflammatory strategies may be more actionable.

Summary

In older heart attack patients, higher levels of a protein called FABP4 were linked to more future heart‑related events, while higher levels of the antimicrobial peptide LL‑37 were linked to fewer such events, even after accounting for other risk factors.

Abstract

The protein known as Fatty Acid-Binding Protein 4 (FABP4), predominantly found in adipocytes, macrophages, and endothelial cells, has emerged as a pivotal biomarker linking inflammation and metabolism in the context of cardiovascular diseases. The present investigation sought to elucidate the influence of FABP4 on the prognostic ramifications for patients experiencing ischemic vascular events, which encompass ischemic cerebrovascular occurrences, myocardial infarctions, and cardiovascular mortality. A total of 1102 consecutive patients diagnosed with acute myocardial infarction (AMI) and aged over 55 years were prospectively enrolled from March 2017 to January 2020. Initially, participants were stratified into three groups according to the tertile levels of FABP4, followed by further categorization based on various lipid profiles and specific inflammatory markers. On follow-up (median 751 days, maximum 1506 days), a total of 158 ischemic events were recorded. 1) In multivariable models meticulously adjusted for age, gender, traditional coronary heart disease factors, Killip classification, and discharge medications, the association of elevated levels of FABP4 (Tertile 3 HR 1.618 [1.061 to 2.468], p=0.026), augmented concentrations of PTX3 (Tertile 3 HR 1.811 [1.211 to 2.710], p=0.004), or LL-37 (Tertile 3 HR 0.651 [0.433 to 0.981], p=0.040) with ischemic risk was markedly intensified. 2) Multivariate HRs associated with 1 standard deviation (SD) (mg/dL) increase in the FABP4 parameters were as follows in different subgroups. 1-SD difference in FABP4 was associated with a 23%, 23%, 21 and 29% increase in ischemic events over after fully adjusted the confounding risk factors among male, patients with hyperlipidemia, hypertension and diabetes respectively. 3) The Kaplan-Meier curve demonstrated significant differences between the tertiles of FABP4 index levels among all enrolled participants (p=0.0180). This study reinforces the utility of FABP4 for enhancing risk stratification specifically among older patients diagnosed with ST-elevation myocardial infarction.

Study Information

Provider

pubmed

Year

2025

Date

2025-02-04T00:00:00.000Z

DOI

10.2147/jir.s494049